Guinness Atkinson Asset Management Inc Acquires 1,378 Shares of Johnson & Johnson (NYSE:JNJ)

Guinness Atkinson Asset Management Inc grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 23.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,316 shares of the company’s stock after purchasing an additional 1,378 shares during the quarter. Guinness Atkinson Asset Management Inc’s holdings in Johnson & Johnson were worth $1,058,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Wescott Financial Advisory Group LLC raised its stake in Johnson & Johnson by 50.5% in the second quarter. Wescott Financial Advisory Group LLC now owns 16,637 shares of the company’s stock valued at $2,432,000 after purchasing an additional 5,581 shares in the last quarter. Zurich Insurance Group Ltd FI raised its stake in Johnson & Johnson by 366.6% in the second quarter. Zurich Insurance Group Ltd FI now owns 145,105 shares of the company’s stock valued at $21,209,000 after purchasing an additional 114,005 shares in the last quarter. Fred Alger Management LLC raised its stake in shares of Johnson & Johnson by 6.1% during the second quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock worth $6,280,000 after acquiring an additional 2,488 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of Johnson & Johnson by 13.0% during the second quarter. Toronto Dominion Bank now owns 1,197,314 shares of the company’s stock worth $174,999,000 after acquiring an additional 137,292 shares in the last quarter. Finally, Trinity Legacy Partners LLC raised its stake in shares of Johnson & Johnson by 5.7% during the second quarter. Trinity Legacy Partners LLC now owns 31,616 shares of the company’s stock worth $4,621,000 after acquiring an additional 1,699 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $145.39 on Thursday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a market cap of $350.04 billion, a PE ratio of 21.04, a price-to-earnings-growth ratio of 2.50 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company’s fifty day moving average price is $148.26 and its 200-day moving average price is $156.12.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same quarter in the previous year, the business posted $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 9.95 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.41%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Analysts Set New Price Targets

Several research analysts have commented on JNJ shares. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 17th. Royal Bank of Canada raised their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Finally, Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $173.27.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.